Enochian BioSciences, Inc. (ENOB) is facing a class action lawsuit (Enochian BioSciences Class Action Lawsuit) alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu’s purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from ENOB to entities he owned; and (7) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you incurred a loss on ENOB stocks purchased between January 17, 2018 and June 27, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Central District of California, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until September 26, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Enochian BioSciences, Inc. Class Action Lawsuit
Enochian BioSciences, Inc. Lawsuit
ENOB Class Action Lawsuit
ENOB Lawsuit
Enochian BioSciences, Inc. (ENOB) Class Action Lawsuit
Enochian BioSciences Class Action Lawsuit,
Enochian BioSciences Class Action,
Enochian BioSciences Lawsuit,
ENOB Class Action Lawsuit,
ENOB Class Action,
ENOB Lawsuit,
ENOB stock